NewEdge Wealth LLC Sells 6,908 Shares of Zoetis Inc. $ZTS

NewEdge Wealth LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 45.8% during the first quarter, HoldingsChannel.com reports. The firm owned 8,165 shares of the company’s stock after selling 6,908 shares during the quarter. NewEdge Wealth LLC’s holdings in Zoetis were worth $965,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. RFG Advisory LLC boosted its stake in shares of Zoetis by 4.9% in the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after buying an additional 80 shares during the period. YANKCOM Partnership raised its holdings in Zoetis by 3.5% in the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock valued at $302,000 after acquiring an additional 81 shares in the last quarter. Quest 10 Wealth Builders Inc. raised its holdings in Zoetis by 4.7% in the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after acquiring an additional 86 shares in the last quarter. Financial Engines Advisors L.L.C. lifted its position in shares of Zoetis by 4.4% during the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock valued at $299,000 after acquiring an additional 87 shares during the period. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its position in shares of Zoetis by 20.9% during the 4th quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 520 shares of the company’s stock valued at $65,000 after acquiring an additional 90 shares during the period. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on ZTS shares. Stifel Nicolaus decreased their price target on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research report on Friday, June 26th. Barclays cut their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Citigroup decreased their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, HSBC dropped their target price on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $118.33.

Insider Activity

In related news, Director Michael B. Mccallister purchased 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average cost of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have purchased 11,650 shares of company stock worth $886,384. Corporate insiders own 0.22% of the company’s stock.

Zoetis Price Performance

Zoetis stock opened at $76.91 on Tuesday. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a 52 week low of $71.47 and a 52 week high of $160.48. The stock has a market capitalization of $32.24 billion, a P/E ratio of 12.75, a price-to-earnings-growth ratio of 1.18 and a beta of 0.75. The stock has a fifty day moving average of $77.27 and a 200-day moving average of $103.71.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period last year, the business earned $1.48 earnings per share. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts expect that Zoetis Inc. will post 6.87 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.